866-997-4948(US-Canada Toll Free)

Age-related Macular Degeneration Partnering 2010-2015

Published By :

Current Partnering

Published Date : May 2015

Category :

Therapeutic Area

No. of Pages : 100 Pages

Age-related Macular Degeneration Partnering 2010-2015 report provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in age-related macular degeneration partnering deals
Top age-related macular degeneration deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Age-related Macular Degeneration Partnering 2009-2014 provides understanding and access to the age-related macular degeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of age-related macular degeneration partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors age-related macular degeneration technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 70 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of HIV partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in age-related macular degeneration partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading age-related macular degeneration deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of age-related macular degeneration partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of age-related macular degeneration technologies and products.

Report scope

Age-related Macular Degeneration Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to age-related macular degeneration trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in age-related macular degeneration dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
The leading age-related macular degeneration deals by value since 2009

In Age-related Macular Degeneration Partnering 2009-2014, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in age-related macular degeneration partnering
2.1. Introduction
2.2. Age-related macular degeneration partnering over the years
2.3. Age-related macular degeneration partnering by deal type
2.4. Age-related macular degeneration partnering industry sector
2.5. Age-related macular degeneration partnering by stage of development
2.6. Age-related macular degeneration partnering by technology type
Chapter 3 – Average deal terms for age-related macular degeneration
3.1 Introduction
3.2 Average deal terms for age-related macular degeneration
3.3 Age-related macular degeneration headline values with median calculation
3.4 Age-related macular degeneration upfront values with median calculation
3.5 Age-related macular degeneration milestone values with median calculation
3.6 Age-related macular degeneration royalty rates with median calculation
Chapter 4 – Active age-related macular degeneration dealmakers
4.1. Introduction
4.2 Most active age-related macular degeneration dealmakers
4.3. Top age-related macular degeneration deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity
Chapter 5 – Age-related macular degeneration dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type
Chapter 6 – Partnering resource center
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products
Table of figures
Figure 1: Age-related macular degeneration partnering since 2010
Figure 2: Age-related macular degeneration dealmaking activity– 2010 to 2015
Figure 3: Age-related macular degeneration partnering by deal type since 2010
Figure 4: Age-related macular degeneration partnering by industry sector since 2010
Figure 5: Age-related macular degeneration partnering by stage of development since 2010
Figure 6: Age-related macular degeneration partnering by technology type since 2010
Figure 7: Age-related macular degeneration deals with a headline value
Figure 8: Age-related macular degeneration deals with upfront payment values
Figure 9: Age-related macular degeneration deals with milestone payments
Figure 10: Age-related macular degeneration deals with royalty rates, %
Figure 11: Top age-related macular degeneration deals by value since 2010
Figure 12: Big pharma – top 50 – age-related macular degeneration deals 2010 to 2015
Figure 13: Big pharma age-related macular degeneration deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – age-related macular degeneration deals 2010 to 2015
Figure 15: Big biotech age-related macular degeneration deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *